All In Biotech

Drug Trial Radar · NCT07270432

Efficacy/ Safety of Product DNN.65.21.005 in Patients With Benign Prostatic Hyperplasia

Randomized Clinical Trial to Evaluate the Safety and Efficacy of Product DNN.65.21.005 in Alleviating Lower Urinary Tract Symptoms in Patients With Benign Prostatic Hyperplasia

Last checked: Nov 20, 2026Latest source record: Dec 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 218 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

218

Planned (sponsor's estimate)

Start

Jan 2026

Primary completion

Apr 2027

Study completion Apr 2027

Sponsor

Sponsor type
Industry
First posted
Dec 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the safety and efficacy of DNN.65.21.005 versus Combodart® in the treatment of benign prostatic hyperplasia

Conditions

  • Prostatic Hyperplasia, Benign

Interventions

  • Product DNN.65.21.005Drug

    One capsule every 24 hours

  • Combodart®Drug

    One capsule every 24 hours

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in International Prostate Symptom Score (IPSS)Time frame: 180 days

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.